Catelle A, Edert D, Renoult E, Cao Huu T
Laboratoire de Microbiologie, CHRU Nancy.
Agressologie. 1992;33 Spec No 2:99-102.
The investigation was carried on 122 waiting renal transplantation hospitalized patients. Detection of HCV antibodies was done before transplantation and after renal transplantation. HCV antibodies were detected by immunosorbent assay (ELISA) for C 100-3 protein of HC virus (Lab. ORTHO). Positive results were checked by a second test (immunoblot RIBA II) to detect antibodies against C100-3, 5-1-1, C33, C22 proteins of HCV genome. Before transplantation, 112 patients were negative and 10 positive. After transplantation, 104 were checked: 103 had identical serology (93- and 10+); only one patient has shown a seroconversion six months after the transplantation, demonstrating the late apparition of HCV antibodies, but immunological status of donor was unknown. Renal transplantation does not seem a risk factor of HCV contamination: only 1 seroconversion on 122 patients or 0.8%: near percentage of French blood donors (0.68%). The percentage of positivity HCV before transplantation (9%) answered with that of European hemophils (5 to 20%). Second generation tests demonstrate a better sensibility and specificity than the first.
该研究对122例等待肾移植的住院患者进行。在移植前和肾移植后检测丙型肝炎病毒（HCV）抗体。采用免疫吸附试验（ELISA）检测HC病毒的C 100-3蛋白（ORTHO实验室）来检测HCV抗体。阳性结果通过第二次检测（免疫印迹RIBA II）进行核实，以检测针对HCV基因组C100-3、5-1-1、C33、C22蛋白的抗体。移植前，112例患者为阴性，10例为阳性。移植后，对104例患者进行了检查：103例患者血清学结果相同（93例阴性和10例阳性）；只有1例患者在移植后6个月出现血清转化，表明HCV抗体出现较晚，但供体的免疫状态未知。肾移植似乎不是HCV感染的危险因素：122例患者中只有1例血清转化，即0.8%，与法国献血者的比例（0.68%）相近。移植前HCV阳性率（9%）与欧洲血友病患者的比例（5%至20%）相符。第二代检测方法比第一代具有更好的敏感性和特异性。
